Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twenty-six research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating, seventeen have given a buy rating and […]
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twenty-six research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating, seventeen have given a buy rating and […]
